Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide – Analyses from a randomised, placebo-controlled study

Jeppesen, Palle Bekker; Pertkiewicz, M.; Forbes, Alastair; Pironi, Loris; Gabe, Simon; Joly, Francisca; Messing, Bernard; Loth, Susanne; Youssef, Nader N.; Heinze, Hartmut; Berghöfer, Peter

doi:10.1016/j.clnu.2013.03.016

Cited by 85 publications

(135 citation statements)

References 23 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…In agreement with the earlier phase II study, 53 these collective results demonstrate the efficacy of teduglutide in reducing PN requirements in PN‐dependent adults. Clinical gains were augmented with increased treatment duration, and perhaps most important, the reductions in infusion frequency experienced by subjects in these trials may potentially have substantial implications for employment, activities, sleep, and finances, 54 as indicated by the association between reductions in PN requirements and significant ( P = .02) improvements in quality of life in STEPS 50 , 55 . The benefits of decreasing PN requirements, as well as allowing patients the freedom and spontaneity that additional days or even hours free from PN offer, cannot be underestimated 54 …”

Section: Discussionmentioning

confidence: 98%

Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults

Naberhuis¹,

Tappenden

2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults

Naberhuis¹,

Tappenden

2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…In the teduglutide clinical trial, quality of life was improved in patients who experienced reduced PN volume, regardless of whether they were treated with drug or placebo. Items in the SBS–Quality of Life score that were significantly improved in the teduglutide‐treated patients were diarrhea/stomal output, gastrointestinal (GI) symptoms, sleep, leisure and everyday activities, social life, physical health, and diet/eating/drinking habits 16 …”

Section: Introductionmentioning

confidence: 99%

Clinical Management of Patients With Parenteral Nutrition–Dependent Short Bowel Syndrome During Teduglutide Therapy

Compher

Boullata

Pickett–Blakely

et al. 2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…Clinical experience in studying the effects of glucagon-like peptide-2 in multicenter clinical trials shows a reduction in stoma output, associated with a mechanism of increased intestinal absorption. Administration of glucagon-like peptide-2 significantly improved the quality of life of patients with short bowel syndrome and a concomitant end stoma [13, 14]. …”

Section: Discussionmentioning

confidence: 99%

Strategies for early metabolic disturbances in patients with an end jejunostomy or end ileostomy. Experience from a specialized Home Parenteral Nutrition (HPN) center

Ławiński

Haraszczuk

Gradowska

et al. 2017

View full text Add to dashboard Cite

IntroductionAn end stoma syndrome is usually the result of an intentional surgical intervention in the course of staged treatment or a complication of surgery. These patients most frequently suffer from water and electrolyte disturbances, malnutrition syndromes caused by malabsorption of trace elements and/or vitamins, and undernutrition.AimTo present early metabolic disturbances observed in patients with an end jejunostomy or end ileostomy syndrome on the first day of their hospitalization in a specialist Home Parenteral Nutrition (HPN) center.Material and methodsThe study included 142 patients with an end stoma syndrome (76 women and 66 men), hospitalized between 2004 and 2014. Patients were divided into two main groups. Group A consisted of 90 patients with an end jejunostomy and group B consisted of 52 patients with an end ileostomy.ResultsAfter comparing the patients with an end jejunostomy vs. those with an end ileostomy, significant differences were found as regards pH (7.34 vs. 7.39, p = 0.043) and BE (3.24 vs. –0.86, p = 0.005). Depending on the lack or possibility of oral food intake, patients in the end jejunostomy group had different levels of the markers phosphate, Mg, Ca, urea, and creatinine, with all of these parameters within normal laboratory limits. When the end ileostomy group was divided into subgroups depending on the lack or possibility of oral food intake, differences in C-reactive protein activity were found (55.6 vs. 25.7, p = 0.041).ConclusionsPatients with an end jejunostomy syndrome are more prone to metabolic acidosis with significant alkali deficiencies.

show abstract

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide – Analyses from a randomised, placebo-controlled study

Cited by 85 publications

References 23 publications

Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults

Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults

Clinical Management of Patients With Parenteral Nutrition–Dependent Short Bowel Syndrome During Teduglutide Therapy

Strategies for early metabolic disturbances in patients with an end jejunostomy or end ileostomy. Experience from a specialized Home Parenteral Nutrition (HPN) center

Contact Info

Product

Resources

About